Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, exercise, or supplement regimen, particularly if you have a chronic health condition, are pregnant, nursing, or taking any medications.

TL;DR

• Urolithin A is not present directly in food. It is produced when specific gut bacteria — principally Gordonibacter urolithinfaciens and Ellagibacter isourolithinifaciens — metabolize ellagitannins from pomegranate, walnuts, raspberries, and related foods.
• An estimated 30–40% of people cannot produce urolithin A from dietary ellagitannins at all, because they lack the relevant gut bacteria. Supplement products bypass this conversion step by delivering urolithin A in pre-formed crystalline structure.
• A 2022 randomized controlled trial published in Nature Aging (Ryu and colleagues, n=88 older adults, 1,000 mg/day for 16 weeks) reported significant improvements in six-minute walking distance, VO2 max, and fatigue-related acylcarnitine markers, alongside measurable increases in mitophagy biomarkers GABARAPL1 and BNIP3L in muscle tissue.
• Calibration: the trial was funded by Amazentis, the maker of the Mitopure brand, and multiple named investigators hold or held Amazentis affiliations. The sample size of 88 is moderate for an aging intervention trial. No randomized controlled trial has examined urolithin A’s effect on longevity outcomes, frailty progression, or mortality in humans.
• Urolithin A’s proposed mechanism — mitophagy induction, the selective autophagy of damaged mitochondria — is mechanistically distinct from fisetin’s senolytic activity (clearing senescent cells from the outside) and ergothioneine’s antioxidant protection (defending healthy mitochondria). These are non-overlapping targets in the cellular aging picture.

Two entry points, one practical question

People who encounter urolithin A in aging research tend to arrive from one of two directions. One group comes through the sarcopenia and muscle-aging literature, where the 2022 RCT generated attention precisely because muscle function improvements from a single oral compound in a properly randomized trial are not common. A different group arrives through gut-longevity research, where the discovery that certain intestinal bacteria synthesize a mitophagy-inducing molecule from fruit polyphenols reframed a basic question: what exactly are longevity-associated gut bacteria doing at the molecular level?

Both paths converge on the same practical question: is this worth supplementing, and does the answer depend on something about your gut microbiome that you cannot easily test for at home?

The honest answer is more layered than either the supplement marketing or reflexive dismissals tend to allow. The 2022 trial exists, is peer-reviewed, and appeared in a high-visibility journal. The Amazentis conflict of interest also exists, is disclosed in the paper, and matters for interpreting functional outcome data. These two facts coexist and need to be held together.

Mitophagy and the Ohsumi framework

Yoshinori Ohsumi’s 2016 Nobel Prize in Physiology or Medicine recognized foundational work on autophagy — the cellular process by which cells identify and dismantle their own damaged components through selective enzymatic machinery. Mitophagy is the mitochondria-specific branch of this pathway. When a mitochondrion becomes sufficiently damaged — exhibiting reduced membrane potential, stalled protein import, or excessive reactive oxygen species output — molecular signals tag that specific organelle for degradation and replacement rather than continued replication.

The capacity for mitophagy declines measurably with age in multiple model organisms and in human tissue samples. Aged skeletal muscle accumulates damaged mitochondria alongside markers of impaired mitophagy signaling — a pattern associated in observational and mechanistic research with reduced ATP production capacity, increased local oxidative stress, and the muscle weakness and fatigue that accompany sarcopenia. Whether the mitophagy decline is a cause, a consequence, or a feature of a larger age-related dysregulation picture remains an active research question.

Urolithin A’s proposed role in this system: it appears to activate mitophagy signaling, specifically through PINK1/Parkin pathway upregulation, in cell culture and animal models. The 2022 RCT is the first human trial to pair this mechanism with a functional outcome measure in older adults, using GABARAPL1 and BNIP3L — both established components of the autophagosome machinery involved specifically in mitophagy — as biomarkers of pathway activation. The specificity of those markers makes the mechanistic signal more interpretable than a generic inflammation or oxidative stress readout.

The 2022 randomized controlled trial: what it found and what it left open

Ryu and colleagues enrolled 88 participants aged 65 and older with low habitual physical activity and randomized them to 500 mg/day urolithin A, 1,000 mg/day urolithin A, or placebo for 16 weeks. The higher-dose arm was the primary analysis.

The results in the 1,000 mg arm: statistically significant improvements in six-minute walking distance and VO2 max relative to placebo; significant reductions in plasma acylcarnitine markers associated with incomplete fatty acid oxidation, used as a surrogate for mitochondrial metabolic function; and significantly elevated GABARAPL1 and BNIP3L gene expression in muscle biopsies. Muscle strength measures — hand grip, leg press — showed trends toward improvement that did not reach statistical significance in the primary analysis.

The conflict of interest situation is worth stating plainly. Amazentis, the Swiss biotech that manufactures Mitopure (pharmaceutical-grade urolithin A), funded the trial. Multiple named investigators hold equity positions, advisory board relationships, or employment with the company, all disclosed in the paper’s Competing Interests statement. Industry-funded intervention trials in the supplement and pharmaceutical space show documented patterns of more favorable outcomes compared to independently funded trials of the same compounds. That is not an accusation of data fabrication — the muscle biopsy biomarker data is relatively direct — but it is a reason to hold functional outcome claims with some caution until independently funded replications are published.

The Amazentis clinical trial portfolio also includes NCT03463551, a registered Phase 2 study targeting sarcopenia in older adults, which represents the broader clinical program surrounding the 2022 RCT. Independent replication by groups without financial relationship to the manufacturer has not yet been published in the accessible literature as of mid-2026.

What the trial does establish with reasonable confidence: at 1,000 mg/day for four months, urolithin A is associated with measurable activation of mitophagy-pathway gene expression in human muscle tissue, alongside functional outcome signals in a moderately sized older adult population. What it does not establish: longevity effects, effects at lower doses, durability beyond the 16-week window, or generalizability to populations with significant comorbidities.

Why your gut bacteria determine whether food works

The production pathway for urolithin A illustrates something about the gut-longevity relationship that most supplement marketing compresses into invisibility. Ellagitannins — the polyphenol family found at meaningful concentrations in pomegranate, walnuts, raspberries, and certain berries — are not urolithin A. They are the raw material that specific gut bacteria transform into urolithin A through a multi-step metabolic conversion requiring organisms from the Eggerthellaceae family, principally Gordonibacter urolithinfaciens and Ellagibacter isourolithinifaciens.

These species are not universally present in human gut microbiomes. Published research examining urolithin metabolites in urine and plasma following pomegranate consumption consistently identifies a subset of participants — across multiple independent studies, estimated at roughly 30–40% of screened populations — who produce little or no urolithin A regardless of ellagitannin intake. These individuals are classified as non-producers or low-converters.

The practical implication is direct. For a non-producer, eating pomegranate or supplementing with pomegranate extract does not meaningfully raise circulating urolithin A. The health associations observed in ellagitannin-rich dietary patterns in population research may partly reflect the biological contribution of urolithin A — but only in individuals whose gut microbiomes carry the conversion machinery. Non-producers on a food-based strategy are getting the ellagitannins without the active metabolite.

This is the specific argument for a pre-formed urolithin A supplement rather than dietary ellagitannin sources: it bypasses individual gut bacteria variability entirely. Whether you are a producer or non-producer, oral urolithin A delivers the compound without requiring the conversion step. The 2022 RCT used Mitopure specifically because it is standardized, pharmaceutical-grade crystalline urolithin A — bioavailability that cannot be replicated through diet regardless of producer status.

The gut-longevity connection here extends to the centenarian microbiome research. The Keio centenarian gut microbiome study has documented gut composition patterns in Japanese individuals living past 100, including enrichment of butyrate-producing species. Whether Gordonibacter or Ellagibacter urolithin-producing taxa are enriched in centenarian gut profiles is a scientifically motivated question that the published Japanese centenarian microbiome literature has not yet specifically addressed. The question of whether “gut bacteria that produce longevity molecules” is a measurable trait of long-lived populations connects logically to this research cluster but remains open.

Japanese food sources of ellagitannins

For confirmed producers — the majority of people — several foods in or associated with Japanese dietary patterns supply meaningful ellagitannin concentrations.

Walnuts (kurumi, 胡桃): Japanese walnut consumption has increased alongside the broader research on ω-3 fatty acids in cardiovascular health. Walnuts are among the highest food sources of ellagitannins by dry weight across published food chemistry analyses, consistently ranking alongside pomegranate. The ω-3 fatty acid contribution (ALA) operates on a separate cardiovascular research axis; the ellagitannin content feeds the urolithin A production pathway independently. Both are reasons walnuts have featured more prominently in Japanese nutritional guidance over the past decade.

Persimmons (kaki, 柿): persimmon is among Japan’s most culturally embedded autumn fruits, and food chemistry analyses confirm meaningful ellagic acid and ellagitannin concentrations, particularly in the skin. The fisetin and Japanese strawberry article covers fisetin from kaki for the senolytic research angle; the ellagitannin-to-urolithin A conversion adds a second mechanistically independent reason persimmons appear in longevity-adjacent dietary research. Senolytic activity (fisetin-mediated) and mitophagy induction (urolithin A-mediated) are non-overlapping pathways, so the two research tracks are additive rather than redundant.

Pomegranate (zakuro, 柘榴): domestic cultivation in Japan is limited, but pomegranate is available through specialty retailers and is widely accessible in supplement extract form. Pomegranate is the most studied ellagitannin source in urolithin A research — most published producer/non-producer characterization studies used pomegranate juice as the test food. Standardized pomegranate extract supplements specify ellagic acid content on the label, which is a proxy for ellagitannin concentration. For non-producers, neither fresh fruit nor extract reliably produces systemic urolithin A.

Compared to fisetin, ergothioneine, and quercetin

Three compounds appearing in the current Choju Lab series target overlapping areas of cellular aging biology through mechanisms that are genuinely distinct. Readers following more than one of them are not chasing the same target through multiple supplements.

Urolithin A versus fisetin: fisetin operates as a senolytic — it appears to induce selective apoptosis in senescent cells, the non-dividing but metabolically active cells that accumulate with age and secrete pro-inflammatory signals into surrounding tissue. Urolithin A’s primary research track targets the damaged mitochondria inside functioning cells, rather than clearing the cell itself. One addresses the aged cell from the outside; the other addresses the failing organelle from within. These are complementary cellular maintenance operations at different biological levels.

Urolithin A versus ergothioneine: ergothioneine is an antioxidant that accumulates via the OCTN1 transporter in mitochondria-dense tissues, cycling between oxidized and reduced forms to buffer reactive oxygen species without being consumed. This is a protective function — reducing damage accumulation in mitochondria that are currently functioning. Urolithin A’s mitophagy induction is a clearance function — removing mitochondria whose damage has accumulated past the threshold where protection would be productive. One shields; the other removes. The ergothioneine and Japanese mushrooms article covers the EGT evidence base fully.

Urolithin A versus quercetin: quercetin’s primary longevity research context is the dasatinib+quercetin senolytic protocol and its general anti-inflammatory activity. Like fisetin, quercetin addresses the senescent cell burden in aged tissue. The quercetin and Japanese onion evidence covers the specific quercetin research track. Urolithin A’s mitophagy mechanism operates below the level of senescent cell dynamics — at the individual organelle rather than the whole-cell level.

What to look for when buying

The commercial urolithin A market has Amazentis’s Mitopure as the most clinically characterized product — it is what was used in the 2022 RCT — alongside competing brands that have entered since the research received mainstream science coverage.

Dose reference: the 2022 trial used 1,000 mg/day as the primary analysis arm and 500 mg/day as a secondary arm. Both showed biomarker changes; the 1,000 mg arm produced clearer functional outcome trends. No independent dose-ranging human trial has established optimal supplementation dosing for any specific clinical outcome, so commercial dose ranges are extrapolated from this single-company RCT rather than derived from multi-study consensus.

Form and purity: urolithin A is a crystalline compound. Softgel and capsule forms are both available commercially. Third-party testing documentation for purity and heavy metal content is more informative than label claims, given the limited regulatory oversight of dietary supplement manufacturing in this category.

Conflict of interest and independent sourcing: the most compelling human evidence for urolithin A comes from Amazentis-funded research. Readers who weight this conflict heavily can engage with the pre-clinical mitophagy research from independent academic groups — which predates and partly underlies the Amazentis clinical program — while acknowledging that the specific functional outcome claims at 1,000 mg/day in humans rest primarily on the company-funded trial.

For Mitopure (the brand used in the 2022 RCT, 500 mg softgel): search Mitopure urolithin A supplement on Amazon.

For Timeline Nutrition Urolithin A (a consumer brand associated with Amazentis technology): search Timeline Nutrition urolithin A on Amazon.

For Elysium Health Urolithin A (an independent brand with third-party testing documentation): search Elysium Health urolithin A on Amazon.

For pomegranate extract — a lower-cost option for confirmed dietary producers wanting to increase ellagitannin supply rather than bypass gut conversion: search pomegranate extract standardized ellagic acid on Amazon.

To compare brands across the current market: search urolithin A supplement capsules 500mg on Amazon.

Side effects and who should discuss this with a clinician

The 2022 RCT reported no significant adverse events at 500 or 1,000 mg/day over 16 weeks in community-dwelling older adults with low physical activity. Urolithin A has an indirect food-use history in producer-phenotype individuals through dietary ellagitannin consumption, though endogenous production levels are substantially below supplement doses.

CYP enzyme interactions: urolithin A inhibits cytochrome P450 enzymes, including CYP3A4, in cell culture at higher concentrations. CYP3A4 metabolizes a broad class of medications — statins, calcium channel blockers, certain immunosuppressants, warfarin, and others. Whether urolithin A at commercially available supplement doses produces clinically meaningful CYP inhibition in humans has not been established in human pharmacokinetic interaction studies. Anyone taking CYP3A4-metabolized medications should discuss urolithin A supplementation with their prescribing clinician before starting.

Mitophagy and cancer biology: mitophagy plays dual roles in cancer biology — associated with tumor-suppressive functions in early-stage disease but also implicated in supporting tumor cell survival under treatment-induced metabolic stress in some research contexts. Anyone in active cancer treatment should discuss any mitophagy-modulating supplement with their treating oncologist before use.

Pregnancy and lactation: no controlled human safety data exists for urolithin A at supplement doses. Standard precautionary avoidance applies.

Who should ask a clinician first: anyone taking multiple medications metabolized by CYP3A4 or CYP2C9; anyone in active cancer treatment or within the post-treatment period; anyone pregnant or nursing; anyone with a diagnosed mitochondrial disease or myopathy where mitophagy dynamics are already altered. The 2022 trial’s safety record does not extend to populations with significant comorbidities — those individuals were excluded from enrollment.

The calibrated position on urolithin A in mid-2026: it is the only compound in the current longevity supplement research space that has shown specific mitophagy biomarker activation alongside functional outcome signals in a properly randomized human trial. That trial has real limitations — primary funder conflict, moderate sample size, short duration, no hard longevity endpoints — and those limitations matter for confidence level. If you want to engage with the underlying biology at a dietary level and are a confirmed producer, Japanese walnuts and persimmons are the most accessible ellagitannin sources. If you are a non-producer, or want to work at RCT-relevant doses without gut-bacteria variability, the pre-formed urolithin A products deliver what diet cannot reliably guarantee — at a price that reflects both production cost and the considerable commercial investment currently surrounding the urolithin A story.

For the broader mitochondrial aging picture, the CoQ10 and ubiquinol evidence article covers the electron transport chain support angle, and the autophagy and Japanese fasting research covers caloric-restriction-mediated autophagy — the dietary route to the same pathway that urolithin A appears to activate pharmacologically.

---

Sources: Ryu et al. 2022. Nature Aging (urolithin A RCT, n=88, 16 weeks, 1,000 mg/day; GABARAPL1/BNIP3L mitophagy biomarkers). | Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1:595–603 (Phase 1 safety and biomarker study). | Ryu D, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016;22(8):879–888 (foundational model-organism data). | Tomás-Barberán FA, et al. Urolithins, the rescue of “old” metabolites to understand a “new” concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Molecular Nutrition & Food Research. 2016;60(8):1780–1788. | González-Sarrías A, et al. Prevalence of the urolithin A and B metabotype in healthy and overweight individuals. Molecular Nutrition & Food Research. Relevant for non-producer prevalence estimates. | ClinicalTrials.gov NCT03463551 (Amazentis Phase 2 sarcopenia trial).